Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1988 1
1989 6
1990 3
1991 1
1992 1
1994 1
1995 4
1996 8
1997 4
1998 5
1999 6
2000 5
2001 3
2002 8
2003 7
2004 10
2005 21
2006 14
2007 16
2008 26
2009 18
2010 15
2011 16
2012 16
2013 27
2014 32
2015 39
2016 43
2017 32
2018 43
2019 47
2020 60
2021 71
2022 73
2023 66
2024 33

Text availability

Article attribute

Article type

Publication date

Search Results

657 results

Results by year

Filters applied: . Clear all
Quoted phrases not found in phrase index: "Cardiomyopathy%2C Hypertrophic", "cardiomyopathy%2C hypertrophic"
Page 1
Diagnosis and Evaluation of Hypertrophic Cardiomyopathy: JACC State-of-the-Art Review.
Maron BJ, Desai MY, Nishimura RA, Spirito P, Rakowski H, Towbin JA, Rowin EJ, Maron MS, Sherrid MV. Maron BJ, et al. J Am Coll Cardiol. 2022 Feb 1;79(4):372-389. doi: 10.1016/j.jacc.2021.12.002. J Am Coll Cardiol. 2022. PMID: 35086660 Free article.
Hypertrophic cardiomyopathy (HCM) is a relatively common often inherited global heart disease, with complex phenotypic and genetic expression and natural history, affecting both genders and many races and cultures. ...
Hypertrophic cardiomyopathy (HCM) is a relatively common often inherited global heart disease, with complex phenotypic and gen …
Management of Hypertrophic Cardiomyopathy: JACC State-of-the-Art Review.
Maron BJ, Desai MY, Nishimura RA, Spirito P, Rakowski H, Towbin JA, Dearani JA, Rowin EJ, Maron MS, Sherrid MV. Maron BJ, et al. J Am Coll Cardiol. 2022 Feb 1;79(4):390-414. doi: 10.1016/j.jacc.2021.11.021. J Am Coll Cardiol. 2022. PMID: 35086661 Free article.
Hypertrophic cardiomyopathy (HCM), a relatively common, globally distributed, and often inherited primary cardiac disease, has now transformed into a contemporary highly treatable condition with effective options that alter natural history along specific personalize …
Hypertrophic cardiomyopathy (HCM), a relatively common, globally distributed, and often inherited primary cardiac disease, has …
Hypertrophic Cardiomyopathy: Clinical Update.
Geske JB, Ommen SR, Gersh BJ. Geske JB, et al. JACC Heart Fail. 2018 May;6(5):364-375. doi: 10.1016/j.jchf.2018.02.010. Epub 2018 Apr 11. JACC Heart Fail. 2018. PMID: 29655825 Free article. Review.
Hypertrophic cardiomyopathy (HCM) is the most common heritable cardiomyopathy, manifesting as left ventricular hypertrophy in the absence of a secondary cause. ...
Hypertrophic cardiomyopathy (HCM) is the most common heritable cardiomyopathy, manifesting as left ventricular hypertro …
Hypertrophic obstructive cardiomyopathy.
Veselka J, Anavekar NS, Charron P. Veselka J, et al. Lancet. 2017 Mar 25;389(10075):1253-1267. doi: 10.1016/S0140-6736(16)31321-6. Epub 2016 Nov 30. Lancet. 2017. PMID: 27912983 Review.
Hypertrophic obstructive cardiomyopathy is an inherited myocardial disease defined by cardiac hypertrophy (wall thickness 15 mm) that is not explained by abnormal loading conditions, and left ventricular obstruction greater than or equal to 30 mm Hg. ...
Hypertrophic obstructive cardiomyopathy is an inherited myocardial disease defined by cardiac hypertrophy (wall thickness 15 m …
Hypertrophic cardiomyopathy: a practical approach to guideline directed management.
Ommen SR, Semsarian C. Ommen SR, et al. Lancet. 2021 Dec 4;398(10316):2102-2108. doi: 10.1016/S0140-6736(21)01205-8. Epub 2021 Sep 30. Lancet. 2021. PMID: 34600606 Review.
In 2020, new hypertrophic cardiomyopathy management guidelines were published, updating and evolving preceding versions. This Seminar provides a concise review and practical guide to the updated recommendations for patients with hypertrophic cardiomyopathy …
In 2020, new hypertrophic cardiomyopathy management guidelines were published, updating and evolving preceding versions. This …
Mavacamten Treatment for Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Ismayl M, Abbasi MA, Marar R, Geske JB, Gersh BJ, Anavekar NS. Ismayl M, et al. Curr Probl Cardiol. 2023 Jan;48(1):101429. doi: 10.1016/j.cpcardiol.2022.101429. Epub 2022 Sep 24. Curr Probl Cardiol. 2023. PMID: 36167226 Review.
Hypertrophic cardiomyopathy (HCM) is the most common heritable cardiomyopathy, yet pharmacological therapy has been unchanged for decades until the recent introduction of mavacamten, a first-in-class cardiac myosin inhibitor. ...
Hypertrophic cardiomyopathy (HCM) is the most common heritable cardiomyopathy, yet pharmacological therapy has been unc …
Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy.
Ho CY, Mealiffe ME, Bach RG, Bhattacharya M, Choudhury L, Edelberg JM, Hegde SM, Jacoby D, Lakdawala NK, Lester SJ, Ma Y, Marian AJ, Nagueh SF, Owens A, Rader F, Saberi S, Sehnert AJ, Sherrid MV, Solomon SD, Wang A, Wever-Pinzon O, Wong TC, Heitner SB. Ho CY, et al. J Am Coll Cardiol. 2020 Jun 2;75(21):2649-2660. doi: 10.1016/j.jacc.2020.03.064. J Am Coll Cardiol. 2020. PMID: 32466879 Free article. Clinical Trial.
BACKGROUND: Patients with nonobstructive hypertrophic cardiomyopathy (nHCM) often experience a high burden of symptoms; however, there are no proven pharmacological therapies. ...(A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertroph …
BACKGROUND: Patients with nonobstructive hypertrophic cardiomyopathy (nHCM) often experience a high burden of symptoms; howeve …
Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy.
Desai MY, Owens A, Geske JB, Wolski K, Naidu SS, Smedira NG, Cremer PC, Schaff H, McErlean E, Sewell C, Li W, Sterling L, Lampl K, Edelberg JM, Sehnert AJ, Nissen SE. Desai MY, et al. J Am Coll Cardiol. 2022 Jul 12;80(2):95-108. doi: 10.1016/j.jacc.2022.04.048. J Am Coll Cardiol. 2022. PMID: 35798455 Free article. Clinical Trial.
BACKGROUND: Septal reduction therapy (SRT), surgical myectomy or alcohol ablation, is recommended for obstructive hypertrophic cardiomyopathy (oHCM) patients with intractable symptoms despite maximal medical therapy, but is associated with morbidity and mortality. . …
BACKGROUND: Septal reduction therapy (SRT), surgical myectomy or alcohol ablation, is recommended for obstructive hypertrophic car …
A Practical Approach to Echocardiographic Imaging in Patients With Hypertrophic Cardiomyopathy.
Mitchell CC, Frye C, Jankowski M, Symanski J, Lester SJ, Woo A, Gilliland Y, Dragulescu A, Abraham T, Desai M, Martinez MW, Nagueh SF, Phelan D. Mitchell CC, et al. J Am Soc Echocardiogr. 2023 Sep;36(9):913-932. doi: 10.1016/j.echo.2023.04.020. Epub 2023 May 7. J Am Soc Echocardiogr. 2023. PMID: 37160197
Hypertrophic cardiomyopathy (HCM) is frequently unrecognized or misdiagnosed. ...
Hypertrophic cardiomyopathy (HCM) is frequently unrecognized or misdiagnosed. ...
Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy.
Hegde SM, Lester SJ, Solomon SD, Michels M, Elliott PM, Nagueh SF, Choudhury L, Zemanek D, Zwas DR, Jacoby D, Wang A, Ho CY, Li W, Sehnert AJ, Olivotto I, Abraham TP. Hegde SM, et al. J Am Coll Cardiol. 2021 Dec 21;78(25):2518-2532. doi: 10.1016/j.jacc.2021.09.1381. J Am Coll Cardiol. 2021. PMID: 34915982 Free article. Clinical Trial.
BACKGROUND: EXPLORER-HCM (Clinical Study to Evaluate Mavacamten [MYK-461] in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy) demonstrated that mavacamten, a cardiac myosin inhibitor, improves symptoms, exercise capacity, and left ventricular outflow …
BACKGROUND: EXPLORER-HCM (Clinical Study to Evaluate Mavacamten [MYK-461] in Adults With Symptomatic Obstructive Hypertrophic Card …
657 results